Click Therapeutics, Inc.

Click Therapeutics is a New York-based digital therapeutics company founded in 2012 that develops and commercializes prescription software medical treatments for psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. The company combines neuroscience with software engineering to create evidence-based digital treatments delivered via mobile platforms and prescribed by physicians. Click's core platform approach includes Prescription Digital Therapeutics (PDTs) and Software-Enhanced Drugs™ (Click SE™), which combine therapeutic software with pharmaceutical agents to enhance clinical outcomes. The company employs advanced AI and adaptive data science technologies, including its proprietary Clickometrics® platform, to personalize patient experiences and optimize treatment efficacy. Key FDA-cleared and investigational programs include CT-152 (Rejoyn™) for major depressive disorder, CT-132 for episodic migraine, and CT-155 for schizophrenia negative symptoms, supported by peer-reviewed clinical evidence and partnerships with major pharmaceutical companies including Otsuka Pharmaceutical and Boehringer Ingelheim.